{"product_id":"unither-five-forces-analysis","title":"United Therapeutics Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnited Therapeutics faces moderate supplier power and high regulatory barriers that protect pricing but intensify R\u0026amp;D costs, while buyer power is constrained by specialty drug demand and payor negotiations; rivalry is moderate due to niche focus, and threat of substitutes is low but emerging biotech innovations pose risk.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore United Therapeutics’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics depends on specific active pharmaceutical ingredients (APIs) and biologic components for treprostinil products; only a handful of GMP-qualified suppliers exist, so supplier concentration gives moderate pricing and timing leverage.\u003c\/p\u003e\n\u003cp\u003eIn 2024 United Therapeutics reported COGS up 6% to $390M, and management cited supplier constraints—so the company uses multi-year supply contracts and dual-sourcing where possible to secure volumes and limit disruption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Medical Device Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe delivery systems for Tyvaso and Remodulin rely on third-party nebulizers and pumps, so device maker disruptions directly hit United Therapeutics’ sales; for example, a 2019 Tyvaso nebulizer recall cut shipments and revenue timing, and in 2024 device component shortages raised fill-rate risk across the sector. High integration raises switching costs—requalifying devices can take 6–18 months and millions in validation—giving suppliers substantial bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Clinical Trial Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnited Therapeutics relies on specialized CROs and niche biotech labs for organ manufacturing and xenotransplantation, creating supplier power since few providers match required capabilities; in 2024, biotech services pricing rose ~7% YoY, boosting supplier margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiological and Animal Model Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe organ manufacturing initiative for United Therapeutics needs steady supplies of genetically modified porcine models and specialized cells; fewer than 30 global facilities meet ABSL-3\/4-equivalent standards for transplant-grade materials, concentrating supply.\u003c\/p\u003e\n\u003cp\u003eThis scarcity lets suppliers charge premiums and demand long-term contracts, risking cost inflation for R\u0026amp;D: outsourced porcine models can cost $15k–$50k per animal and bespoke cell lines $50k–$200k, affecting pipeline economics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal ABSL-grade suppliers \u0026lt;30 facilities\u003c\/li\u003e\n\u003cli\u003ePorcine model cost $15k–$50k each\u003c\/li\u003e\n\u003cli\u003eCell lines $50k–$200k per line\u003c\/li\u003e\n\u003cli\u003eHigh supplier leverage on long-term R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh GMP (Good Manufacturing Practices) compliance means supplier changes can take 18–36 months and cost millions in revalidation; United Therapeutics (UTC) reported 2024 manufacturing spend of about $420M, so switching raises operational and regulatory risk.\u003c\/p\u003e\n\u003cp\u003eFDA actions risk product holds and $0.5–1B revenue disruption for blockbusters, so UTC stays with proven, higher-cost suppliers, increasing supplier bargaining power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP revalidation: 18–36 months\u003c\/li\u003e\n\u003cli\u003eUTC manufacturing spend 2024: ~$420M\u003c\/li\u003e\n\u003cli\u003ePotential revenue risk per product: $0.5–1B\u003c\/li\u003e\n\u003cli\u003eRegulatory friction limits low-cost switching\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier bottlenecks threaten United Therapeutics: high costs, long revalidation, single-source risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate–high power for United Therapeutics due to few GMP\/API\/device\/CRO providers, long revalidation (18–36 months) and concentrated ABSL-grade organ sources (\u0026lt;30 facilities), raising costs and disruption risk; 2024: COGS $390M, manufacturing spend ~$420M, porcine models $15k–$50k, cell lines $50k–$200k, potential $0.5–1B revenue hit per product.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Range\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e$390M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing spend\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eABSL facilities\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;30 global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePorcine model\u003c\/td\u003e\n\u003ctd\u003e$15k–$50k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell line\u003c\/td\u003e\n\u003ctd\u003e$50k–$200k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevalidation time\u003c\/td\u003e\n\u003ctd\u003e18–36 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for United Therapeutics assessing competitive rivalry, supplier and buyer power, substitution risks (including generics and alternative therapies), and barriers to entry, highlighting regulatory, R\u0026amp;D intensity, and IP protections that shape its market position and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for United Therapeutics—quickly gauge competitive intensity, supplier\/payer pressure, and biotech-specific threats to prioritize strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Specialty Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of United Therapeutics’ sales flows through a handful of specialty pharmacies—about 60–70% of specialty-channel revenue in 2024—giving these distributors gatekeeper power to demand rebates, preferred formulary placement, and fast delivery windows.\u003c\/p\u003e\n\u003cp\u003eTheir scale enables negotiation of terms that can shave margins; a single national pharmacy can represent 15–25% of patient scripts for a product, pressuring pricing and co-pay assistance arrangements.\u003c\/p\u003e\n\u003cp\u003eBecause these pharmacies run patient education and adherence programs that drive refill rates and outcomes, United Therapeutics depends on them for commercial success, which increases customers’ bargaining leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers and Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsurance firms and pharmacy benefit managers (PBMs) control formulary placement and reimbursement tiers, pushing intense downward pressure on United Therapeutics pricing; in 2024 PBMs managed ~80% of US prescriptions, concentrating buyer power.\u003c\/p\u003e\n\u003cp\u003eIf a major payor prefers a rival drug or a generic, United Therapeutics could lose rapid access—payers often shift tier placement within 1–2 quarters after new evidence or rebates.\u003c\/p\u003e\n\u003cp\u003eUnited Therapeutics must prove superior clinical outcomes and cost-effectiveness—pivotal trials and real-world evidence showing meaningful survival or hospitalization reductions are key to retain premium reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Government Drug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith the 2022 Inflation Reduction Act and similar global rules, government payers now have stronger price-negotiation power; Medicare Part D negotiations could affect drugs like United Therapeutics’ Remodulin and Orenitram, where Medicare covers roughly 40–60% of pulmonary hypertension patients in the US.\u003c\/p\u003e\n\u003cp\u003eFederal negotiation and potential inflation-linked rebates cap United Therapeutics’ ability to raise list prices annually; the company reported net price increases contributed 6–8% of revenue growth in recent years, a lever now constrained. \u003c\/p\u003e\n\u003cp\u003eThis buyer power reduces margin flexibility and raises revenue risk: if negotiated discounts reach 20–30% on key drugs, EPS could decline materially absent offsetting volume gains or cost cuts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Clinical Choice\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwhile individual pulmonary hypertension patients have low bargaining power organized advocacy groups association members in shape formulary priorities and guideline visibility affecting demand for united therapeutics therapies.\u003e\n\u003cpunited therapeutics spends\u003e$100M annually on patient support and copay programs to foster brand loyalty so patients specifically request its drugs, but rising entrants (6 new PAH therapies 2019–2025) give physicians\/patients more choice based on route and ease of use.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy groups influence formularies\u003c\/li\u003e\n\u003cli\u003eCompany spends \u0026gt;$100M\/year on patient support\u003c\/li\u003e\n\u003cli\u003e~15,000-member PHA raises treatment visibility\u003c\/li\u003e\n\u003cli\u003e6 new PAH therapies entered 2019–2025, increasing choice\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/punited\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth System and Hospital Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cplarge hospital systems and academic medical centers buy high-cost therapies in bulk negotiate institutional contracts using volume to secure discounts or bundled pricing for inpatient pulmonary hypertension drugs the top us health represented roughly of admissions amplifying leverage against makers like united therapeutics.\u003e\n\u003cpas consolidation rises hospital m transactions totaled in and continued purchasing groups press for rebates outcomes-based pricing panel access squeezing list-price realization margin on specialty products.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop 20 systems ≈30% of admissions (2024)\u003c\/li\u003e\n\u003cli\u003e124 hospital M\u0026amp;A deals in 2023\u003c\/li\u003e\n\u003cli\u003eContracts target inpatient discounts, bundled pricing\u003c\/li\u003e\n\u003cli\u003ePrice pressure reduces net price realization for biotech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pas\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers’ Leverage Threatens PAH Margins: PBMs, Specialty Pharmacies, Medicare Drive Cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (specialty pharmacies, PBMs, payors, large hospital systems) exert strong leverage: specialty pharmacies = 60–70% of channel sales (2024); PBMs manage ~80% of US scripts (2024); Medicare covers 40–60% of PAH patients; United Therapeutics spends \u0026gt;$100M\/year on patient support; 6 new PAH therapies entered 2019–2025—net discounts of 20–30% can materially cut EPS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eKey stat (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e60–70% channel sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003e~80% scripts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare PAH share\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eUnited Therapeutics Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact United Therapeutics Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is part of the full, professionally formatted report you’ll be able to download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou’re previewing the final file—precisely the same deliverable that will be available to you instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747231379833,"sku":"unither-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/unither-five-forces-analysis.png?v=1772196327","url":"https:\/\/matrixbcg.com\/products\/unither-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}